Correspondence 0001493152-23-027194 from Vitro Biopharma, Inc. (VTRO) (CIK 0000793171)
Vitro Biopharma, Inc. (VTRO) (CIK 0000793171)
Date: Aug. 8, 2023 · CIK: 0000793171 · Accession: 0001493152-23-027194
AI Filing Summary & Sentiment
File numbers found in text: 333-267366
Letter
Cherry Creek Drive South, Suite 720
Denver, Colorado 80209
August 8, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Attn: Joshua Gorsky, Suzanne Hayes, Julie Sherman and Kevin Vaughn
Re: Vitro Biopharma, Inc.
Registration Statement on Form S-1
Filed on July 17, 2023
File No. 333-267366
WITHDRAWAL OF REQUEST FOR ACCELERATION OF EFFECTIVENESS
Ladies and Gentleman:
Please refer to the acceleration request (the “Acceleration Request”) submitted on August 4, 2023 by Vitro Biopharma, Inc., in which we requested acceleration of the effective date of the above-referenced Registration Statement on Form S-1 to August 8, 2023, at 5:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at such time and we hereby formally withdraw the Acceleration Request.
If you have any questions regarding this request, please contact Scott Berdan of Polsinelli PC, our outside counsel, at (303) 583-8235.
Thank you for your assistance with this matter.
Sincerely,
VITRO
BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
3200
Cherry Creek Drive South, Suite 720
Denver,
Colorado 80209
August
8, 2023
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attn:
Joshua Gorsky, Suzanne Hayes, Julie Sherman and Kevin Vaughn
Re:
Vitro
Biopharma, Inc.
Registration
Statement on Form S-1
Filed
on July 17, 2023
File
No. 333-267366
WITHDRAWAL
OF REQUEST FOR ACCELERATION OF EFFECTIVENESS
Ladies
and Gentleman:
Please
refer to the acceleration request (the “Acceleration Request”) submitted on August 4, 2023 by Vitro Biopharma, Inc.,
in which we requested acceleration of the effective date of the above-referenced Registration Statement on Form S-1 to August 8, 2023,
at 5:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that
such Registration Statement be declared effective at such time and we hereby formally withdraw the Acceleration Request.
If
you have any questions regarding this request, please contact Scott Berdan of Polsinelli PC, our outside counsel, at (303) 583-8235.
Thank
you for your assistance with this matter.
Sincerely,
VITRO
BIOPHARMA, INC.
/s/
Nathan Haas
Name:
Nathan
Haas
Title:
Chief
Financial Officer
cc:
Scott
Berdan, Esq., Polsinelli PC
Tyler
Weigel, Esq., Polsinelli PC
Shashi
Khiani, Esq., Polsinelli PC